786.347.3500
info@demerx.com
DemeRx IB, Inc. CEO Deborah Mash joined Proactive New York to discuss the group’s joint venture with Atai Life Sciences (NASDAQ:ATAI), focused on developing ibogaine to treat opioid use disorder. Mash says the group has recently dosed its first patient with an oral form of......
12 October, 2021Derived from the iboga plant, ibogaine is a psychoactive compound that could have huge potential as a long-term solution to addiction. ATAI Life Sciences and DemeRx are soon initiating clinical trials to test its efficacy. According to the World Health Organization around 3.3 million people die every......
12 June, 2021Today’s episode features Deborah Mash, founder and CEO of DemeRx, a clinical stage company developing ibogaine therapies to treat substance use disorders. In this episode, we discuss: The science, experience and the safety behind Ibogaine’s “neurochemical reset” Navigating US drug regulatory system and securing Intellectual Property Deborah’s......
04 May, 2021Miami-based Deborah Mash is one of the world’s foremost experts on the hallucinogenic drug Ibogaine. She is the CEO and Founder of DemeRx Inc., a clinical stage drug development company advancing Ibogaine and its active metabolite Noribogaine for the treatment of opioid use disorder. Most......
21 October, 2020Yale Psychedelics Science Group presents Dr. Deborah Mash – Breaking the Cycle of Opioid Dependence with Ibogaine Watch full webinar: https://www.youtube.com/watch?v=itqZVfWeq0A&ab_channel=YalePsychedelicScienceGroup...
05 June, 20202020 has been a tough year for global markets and this is a trend that we have been closely following. During the last year, we have seen a rapid increase in the number of companies that are in the psychedelic market and this is a......
30 April, 2020CEO and co-founder of ATAI Life Sciences, Florian Brand explains why one psychedelic medicine might provide the key to fighting opioid addiction. Read full article: https://www.epmmagazine.com/opinion/how-psychedelic-medicine-is-being-used-in-the-fight-to-end-o/ ...
27 March, 2020“Ibogaine made them ready for change,” says researcher Deborah Mash, PhD. Mash has been studying the effects of ibogaine since 1992. A psychedelic compound derived from the bark of a shrub native to western central Africa, ibogaine is being used as a potent addiction disruptor (specifically......
27 February, 2020Ira Pastor, ideaXme exponential health ambassador and founder of Bioquark interviews Dr. Deborah Mash, Professor of Neurology and Molecular and Cellular Pharmacology at the Leonard M. Miller School of Medicine, and Director of the Brain Endowment Bank at the University of Miami. Listen to podcast: https://radioideaxme.com/2019/07/30/ibogaine-therapies/ ...
30 July, 2019The United States is struggling with a staggering opioid addiction epidemic—often starting with legitimate pain pill prescriptions, and ending with full-blown abuse. It is estimated that there are four million people in America who are addicted to pain medicines or heroin, with a growing number......
20 October, 2016When Dr. Deborah Mash met the grandfather of ibogaine treatment, Howard Lotsof, and observed first-hand the effectiveness that ibogaine had for addiction interruption, she knew she’d found something special. Within a relatively short period of time, she petitioned for and received FDA approval to begin......
24 April, 2016Heroin addicts and alcoholics have said ibogaine helped them kick addiction, so why is it illegal in the United States? Read full article: https://demerx.com/wp-content/uploads/2020/06/Could-this-drug-help-millions-of-American-addicts-Al-Jazeera-America.pdf...
19 May, 2014News from Kron 4, San Fransisco. Dr. Mash is one of the few scientists in the world to study ibogaine, a mild hallucinogen that comes from the root of a shrub found in West Africa and was rumored to have the amazing ability to help......
07 May, 2011